Overview of Nuzyra

Quick Facts

Property	Description
Active ingredient	Omadacycline tosylate
Form	Tablet (oral), Lyophilized powder (IV infusion)
Pharmacological class	Aminomethylcycline, Tetracycline-class antibiotic
Common use	Fighting bacterial infections in adults
Origin	Semisynthetic compound

What is Nuzyra and What Class of Antibiotic is it?

Nuzyra is the trade name for the prescription-only antibacterial drug Omadacycline, which is formally classified as a semisynthetic aminomethylcycline antibiotic. Omadacycline is a single-ingredient product used to combat infections caused by susceptible bacteria in adult patients. It belongs to the broader tetracycline-class of antibiotics but is clinically recognized for its advanced structural properties that help overcome common resistance issues. The drug entity is developed and marketed by Paratek Pharmaceuticals, Inc., targeting complicated infections.

How Does Omadacycline Differ from Older Tetracycline Antibiotics?

Omadacycline has been specifically engineered to overcome resistance mechanisms that limit the effectiveness of older tetracyclines, making it a distinctive therapeutic agent. Omadacycline is designed to circumvent two primary bacterial defense strategies: the efflux pumps that actively expel the medicine, and ribosomal protection that prevents the drug from binding to the bacteria's 30S ribosomal subunit. This structural advancement ensures that the drug maintains efficacy against organisms that have developed defenses against older analogues.

What are the Available Forms of Nuzyra?

Nuzyra is supplied in two distinct dosage forms for administration to adult patients: a solid tablet intended for the oral route of administration, and a lyophilized powder in a single-dose vial for reconstitution into a solution for intravenous (IV) infusion. The active ingredient, Omadacycline tosylate, is present in both preparations. This dual-formulation strategy offers a distinct advantage in patient care, allowing for flexible treatment protocols, such as transitioning a patient from intravenous to oral therapy.

Regulatory References

NIH, National Library of Medicine

What side effects are possible with Nuzyra?

Possible Side Effects and Safety Information

The official safety profile for omadacycline (Nuzyra) describes potential adverse effects based on frequency and the affected body system, as established by regulatory authorities.

Adverse reactions are classified into categories such as Very Common and Common in regulatory labeling. Reactions classified as Very Common include local effects at the administration site, such as infusion site pain and phlebitis, which typically relate to the intravenous formulation. Common reactions often affect the gastrointestinal system (nausea, vomiting, diarrhea, abdominal pain) and the hepatobiliary system, which may show increases in liver enzymes (ALT, AST, and GGT). Other commonly reported effects include headache, hypertension, and vaginal candidiasis.

Regulatory documents highlight several serious adverse reactions, including the risk of severe Hepatotoxicity (liver injury) and Clostridioides difficile-Associated Diarrhea (CDAD). The possibility of Intracranial Hypertension (elevated pressure within the skull) is also noted, particularly with long-term use, which is a known constraint of the tetracycline class.

Safety limitations must be considered for specific populations: the drug is generally avoided in children under eight years of age and during the second and third trimesters of pregnancy due to the risk of permanent tooth discoloration and inhibition of bone growth. The medicine must not be used by individuals with a severe hypersensitivity to omadacycline or any other tetracycline-class antibiotic. Additionally, photosensitivity—an exaggerated reaction to sun or UV exposure—is a documented safety constraint.

Overdose and Emergency Response

Overdose and When to Seek Help

The information regarding overdose for Nuzyra (omadacycline) is strictly based on findings documented in official government regulatory labeling.

Required Emergency Actions

If an overdose is suspected, official regulatory information mandates that immediate medical attention must be sought. Patients are instructed to contact a poison control center or emergency room at once when exposure exceeds the prescribed dosage. The regulatory documents emphasize this action as management depends on immediate professional care.

Management and Physiological Findings

Treatment of omadacycline overdose is defined as strictly symptomatic and supportive treatment. This means that care is focused on addressing any clinical signs that may arise and maintaining essential physiological functions. Importantly, the official prescribing information notes that no specific antidote is known for omadacycline. Furthermore, regulatory documents contain the formal physiological finding that the drug is not removed in significant amounts by hemodialysis, a critical consideration for medical professionals managing severe exposure cases.

Documented Presentation

No specific clinical signs, symptoms, or laboratory abnormalities associated with omadacycline overdose are explicitly detailed in the official OVERDOSAGE sections of regulatory labels. The official profile focuses entirely on required emergency actions and the constraints of supportive medical management.

Therapeutic Uses of Nuzyra

What Nuzyra Treats: Main Uses and Benefits

This medication is used to manage infections in adult patients. Nuzyra is commonly applied across therapeutic domains involving heightened systemic burden to address Community-Acquired Bacterial Pneumonia (CABP) and complicated Acute Bacterial Skin and Skin Structure Infections (ABSSSI).

It is relevant for managing symptoms that create noticeable physiological strain, such as fever, cough, significant localized pain, redness, and swelling. For infections caused by susceptible bacterial pathogens, including strains that exhibit multidrug resistance (MDR), the medication is commonly used to help with symptomatic management in challenging clinical contexts. This application assists with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Support for Acute Infections	Description
Primary Therapeutic Use	Managing specific bacterial infections in adults
Symptom Focus	Contributes to easing acute pain, inflammation, and systemic distress
Key Benefit	Helps improve comfort during periods of heightened symptoms
Context of Use	Conditions characterized by periods of heightened symptoms, like CABP and ABSSSI

Regulatory References

omadacycline product information provided to the FDA

Eligibility and Restrictions for Use

Who Can and Cannot Use Nuzyra? (Omadacycline)

Nuzyra (omadacycline) is an antibiotic primarily approved for treating adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). A healthcare provider must evaluate a patient’s specific infection and medical history to determine if this medication is appropriate.

Who Should NOT Use Nuzyra? (Contraindications)

The most critical contraindications and warnings for Nuzyra include:

Category	Specific Concern
Allergy	Individuals with a known hypersensitivity to omadacycline, any tetracycline-class antibacterial drug, or any component of Nuzyra.
Pregnancy	Pregnant women should not use Nuzyra. Tetracycline-class drugs can cause permanent tooth discoloration and slow bone growth in the fetus.
Pediatrics	Children younger than 8 years old should not be given this drug. It carries a risk of permanent tooth discoloration and effects on bone development in this age group.

Important Considerations

Use with caution is advised for patients with a history of intracranial hypertension (pseudotumor cerebri) or a predisposition to photosensitivity reactions, as these are known risks associated with the tetracycline class of antibiotics.

What should I know about interactions with other medicines?

Interactions with other medicines and products for Nuzyra (Omadacycline)

Official regulatory information highlights two primary categories of clinically significant interactions for omadacycline, which require specific patient management or timing separation.

1. Interactions Affecting Absorption (Chelation)

Oral omadacycline forms chelates with polyvalent cations, leading to a substantial decrease in the amount of drug absorbed into the body (exposure). This interaction is strictly documented for both oral and intravenous administration.

Interacting Substances:

Antacids containing aluminum, calcium, or magnesium.
Iron-containing preparations and supplements.
Multivitamins and other polyvalent cation-containing products (including dairy products).
Bismuth subsalicylate.

Regulatory Requirement: To ensure proper absorption, official labeling mandates time separation. For oral dosing, these cation-containing products, including dairy, must be avoided for at least 4 hours after taking omadacycline. The intravenous formulation must not be administered in the same line as solutions containing multivalent cations.

2. Pharmacodynamic Interactions

Concomitant use of omadacycline with anticoagulant therapy (such as warfarin) may potentiate the effect of the anticoagulant. This is a class effect of tetracyclines, which have been observed to depress plasma prothrombin activity. Close monitoring of the patient’s anticoagulant status is required if these medicines are used together.

3. Food Interactions

Food significantly reduces the oral bioavailability of omadacycline. Therefore, the oral formulation must be taken under fasting conditions, and no food or drink (other than water) should be consumed for 2 hours after the dose.

Mechanism of Action

Omadacycline works by acting as a specific inhibitor within the bacterial cell, directly binding to the 30S ribosomal subunit. This molecular interaction physically blocks the entry of transfer RNA (tRNA), immediately halting the elongation of the peptide chain. This action suppresses the fundamental cellular process of protein synthesis, leading to the cessation of bacterial growth (bacteriostasis) and the subsequent physiological response of reduced bacterial viability.

The molecule's structure confers the capacity to circumvent bacterial resistance mechanisms. Omadacycline maintains functional activity against organisms that employ major bacterial efflux pumps to expel drugs, and it maintains high affinity to the target even in the presence of common ribosomal protection proteins. This capacity allows the anti-proliferative physiological effect to be exerted against organisms with these defense systems.

However, the mechanism is intrinsically constrained by its molecular profile, rendering it less effective against bacteria that utilize certain non-tetracycline-specific efflux systems or those that harbor the drug-degrading enzyme TetX. This defines the specific biological boundaries within which the drug's mechanism can successfully execute the inhibition of protein synthesis.

Dosage and Administration Information

This information details the administration instructions for Nuzyra (omadacycline).

Dosage and Administration

Treatment is administered as either an intravenous (IV) infusion or an oral tablet for a total duration of 7 to 14 days. A loading dose is used at the start of therapy, followed by a lower, daily maintenance dose.

Regimen	Loading Dose	Maintenance Dose
IV Infusion	200 mg over 60 minutes on Day 1 OR 100 mg over 30 minutes, twice on Day 1.	100 mg over 30 minutes once daily.
Oral Tablet (CABP)	300 mg twice on Day 1.	300 mg once daily.
Oral Tablet (ABSSSI)	450 mg once daily on Day 1 and Day 2.	300 mg once daily.

Administration Requirements

Oral Tablets

Oral tablets must be taken on an empty stomach. Patients must fast for at least 4 hours before taking the dose and not consume food or drink (except water) for 2 hours after dosing. Additionally, dairy products, antacids, or multivitamins must not be consumed for 4 hours following the dose.

Intravenous (IV) Infusion

For IV use, the product must be reconstituted and further diluted under aseptic conditions, typically to a 100 mL volume using 0.9% Sodium Chloride or 5% Dextrose Injection. The 200 mg dose is infused over 60 minutes, and the 100 mg dose over 30 minutes. It must be administered through a dedicated intravenous line or Y-site, and not with any solution containing multivalent cations (e.g., calcium and magnesium).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nuzyra

Evidence for Use in Acute Bacterial Skin Infections (ABSSSI)

The primary research available for omadacycline for acute bacterial skin and skin structure infections (ABSSSI) comes from short-term Phase 3 randomized controlled trials (RCTs). In these studies, omadacycline was evaluated in adult patients with complicated skin infections and was compared against a standard-of-care antibiotic. Researchers mainly used two outcomes to track the status of symptoms: the Early Clinical Response (ECR), assessed within the first 48 to 72 hours, and the final clinical status assessed roughly one to two weeks after the last dose. Follow-up durations were limited, and data for certain groups remain insufficient, providing limited insight into long-term changes.

Evidence for Use in Community-Acquired Bacterial Pneumonia (CABP)

Omadacycline was evaluated in adults with moderate to severe community-acquired bacterial pneumonia (CABP) through short-term Phase 3 RCTs. The research primarily examined patient survival and specific outcomes monitoring measures related to physiological strain or stress, such as change in respiratory symptoms. Final assessments of clinical status were made shortly after the last dose. One pivotal study was observed in some studies to have a numerical difference in mortality between the omadacycline group and the comparator, particularly among older adult patients with pre-existing medical conditions, which was documented in the official review materials.

Evidence in Contexts of Resistance and Secondary Infections

Evidence concerning omadacycline’s evaluation in patients with secondary bacteremia and infections involving multidrug-resistant (MDR) organisms is derived from post-hoc analyses of the main Phase 3 trials, focusing on a small subgroup of patients. These analyses contribute to the broader evidence landscape regarding clinical status in infections involving bacteria known to be resistant to older tetracyclines. Because this evidence relies on a small sample size, certainty remains low for these specific contexts, and results apply only to the populations studied.

What Remains Uncertain in the Research Landscape

The evidence highlights areas where research is ongoing. This includes the need for continued surveillance following the observed numerical difference in mortality rates in the CABP studies. The observation underscores that findings describe group patterns, not personal outcomes. Comparative evidence is lacking for many potential special populations, and the follow-up durations were limited in all primary trials. The clinical status in highly specialized populations are areas where evidence remains limited and evidence quality varies across studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Nuzyra (FAQ)

Q: How quickly does Nuzyra start working?

A: Studies for skin infections evaluated patient status early in treatment, tracking a measure called Early Clinical Response (ECR) between 48 and 72 hours after the start of therapy. This early tracking indicates the timeframe researchers used to check for initial changes in symptoms. Individual patient outcomes and how quickly a person feels better can vary, and official information describes general patterns.

Q: What happens if I miss a dose of Nuzyra?

A: Regulatory-cited patient instructions advise taking the dose as soon as it is remembered. If it is nearly time for the next scheduled dose, official information advises skipping the missed dose and taking the next dose as planned. Official information states that double doses or extra medicine should not be taken to compensate for a missed dose.

Q: Is nausea a common side effect of Nuzyra?

A: Yes, official product information lists nausea as a very common side effect. During clinical studies, this effect was reported by up to 30% of patients.

Q: Can Nuzyra cause diarrhea?

A: Official safety information notes that diarrhea is a common adverse effect associated with this medicine. Furthermore, there is a specific warning about the potential for developing severe diarrhea caused by a type of bacteria known as Clostridioides difficile (CDAD).

Q: Are headaches a frequent side effect of Nuzyra?

A: Yes, official documents describe headache as a common side effect. This means it was reported by between 1% and 10% of patients during clinical studies.

Q: What conditions make someone ineligible to use Nuzyra?

A: Official documents list known hypersensitivity (severe allergy) to omadacycline or any tetracycline-class antibiotic as a reason not to use this drug. It is also generally avoided in children under 8 and pregnant women due to risks to bone and tooth development. Caution is additionally noted for patients with a history of intracranial hypertension (high pressure inside the skull).

Q: How is Nuzyra different from doxycycline?

A: Nuzyra is classified as an aminomethylcycline, which is a newer type of tetracycline-class antibiotic. It is structurally engineered to be active against some bacteria that have developed resistance to older tetracycline drugs, such as doxycycline, by overcoming specific bacterial defense systems.

Q: Is Nuzyra the same as minocycline?

A: No, Nuzyra (omadacycline) is not the same as minocycline. While both are in the broader tetracycline class, Nuzyra belongs to the newer aminomethylcycline subclass. Its structure is different and is specifically designed to work against certain bacterial resistance mechanisms that affect older tetracyclines.

Q: Is Nuzyra a type of penicillin?

A: No, Nuzyra is not a penicillin. According to its classification in official product information, omadacycline is a tetracycline-class antibiotic.

Q: Is Nuzyra used for infections other than skin and lung infections?

A: Official regulatory documents indicate that the drug is approved only for the treatment of certain bacterial skin infections (ABSSSI) and community-acquired bacterial pneumonia (CABP) in adult patients.

Q: What over-the-counter medicines should be avoided while taking Nuzyra?

A: Official information mandates specific time separation for oral Nuzyra from any product containing polyvalent cations (positively charged minerals). This includes common over-the-counter items like antacids, iron supplements, multivitamins, and bismuth subsalicylate. The labeling mandates that these products must be separated from the oral tablet dose by a specific time frame.

Q: Is Nuzyra a controlled substance?

A: No, Nuzyra (omadacycline) is a prescription-only medicine. However, it is not classified as a controlled substance by regulatory authorities.

Q: Does Nuzyra treat MRSA infections?

A: Official regulatory documentation indicates that the drug is approved for certain skin infections (ABSSSI) caused by susceptible microorganisms, including Methicillin-Resistant Staphylococcus aureus, commonly known as MRSA.

Q: Is Nuzyra safe to use while breastfeeding?

A: The manufacturer generally advises against breastfeeding during treatment and for four days following the last dose. This caution is based on the unknown effects of the medicine on the nursing infant and the theoretical class risk of side effects, such as permanent tooth discoloration.

Q: Does Nuzyra affect kidney function?

A: Official regulatory information confirms that no dose adjustment is necessary for patients who have any level of impaired kidney function, including those undergoing dialysis.

Q: How long does Nuzyra stay in your system after the last dose?

A: The official clinical pharmacology data indicates that omadacycline has a mean elimination half-life of about 16 hours. The half-life describes the time it takes for the amount of drug in the body to be reduced by half.

Q: Can Nuzyra affect the heart rhythm?

A: Common side effects reported in clinical trials include hypertension, or high blood pressure. Less frequently reported events included certain heart rhythm changes, such as tachycardia (a fast heart rate) and atrial fibrillation.

Q: What color are Nuzyra tablets?

A: The oral tablets are described in official pill identification documents as being yellow and four-sided.

Q: Do studies suggest that Nuzyra causes antibiotic resistance?

A: The official label for the medicine includes a general warning common to all antibacterial drugs. It states that using an antibiotic when a bacterial infection is not suspected increases the risk of developing drug-resistant bacteria.

Q: Is Nuzyra available as a generic drug?

A: Nuzyra (omadacycline) is currently available only as a brand-name medication and is not yet available as a generic drug.

Q: What is the typical age range of patients who use Nuzyra?

A: The drug is officially indicated for use in adult patients only. Furthermore, official contraindication warnings advise against its use in children under the age of 8.

How should Nuzyra be stored and disposed of?

Storage Requirements for Nuzyra (omadacycline)

The original product—both the tablets and the lyophilized powder for injection—must be stored at controlled room temperature, specifically 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F).

The product must not be frozen.
The tablets should be kept out of the reach of children and stored in their original container.

IV Solution Stability (After Dilution)	Maximum Storage Time
Room Temperature (leq 25 C / 77 F)	24 hours
Refrigerated (2 C to 8 C / 36 F to 46 F)	7 days

Handling and Disposal

Reconstitution of the IV powder must be performed under aseptic conditions and the solution must be further diluted within one hour. Any unused portion of the prepared intravenous solution must be discarded. For general disposal of expired or unneeded medicine, users are directed to dispose of the product according to local regulations, rather than flushing it down the toilet.

Nuzyra